Conjugated estrogens + medroxyprogesterone acetate

Intervention2 papers3 findingsPubChem 45357473PubChem 6279ChEBI 6716

Human trial1

Associations

3

Fractures

downin humans1RR 0.78High certainty

1 study

Conjugated estrogens + medroxyprogesterone acetate lowers the risk of fractures in humans (RR 0.78, 95% CI 0.71 to 0.86).
Reviewpostmenopausal women with an intact uteruscombined continuous5.6 yearsfemalesn = 16,608
Long-term hormone therapy for perimenopausal and postmenopausal women · The Cochrane database of systematic reviews · 4 Sep 2026

Venous thromboembolism

upin humans1RR 2.03High certainty

1 study

Conjugated estrogens + medroxyprogesterone acetate raises the risk of venous thromboembolism in humans (RR 2.03, 95% CI 1.55 to 6.64).
Reviewpostmenopausal women with an intact uteruscombined continuous5.6 yearsfemalesn = 16,608
Long-term hormone therapy for perimenopausal and postmenopausal women · The Cochrane database of systematic reviews · 4 Sep 2026

Venous thromboembolism →

Stroke

upin humans1RR 1.39High certainty

1 study

Conjugated estrogens + medroxyprogesterone acetate raises the risk of stroke in humans (RR 1.39, 95% CI 1.09 to 2.09).
Reviewpostmenopausal women with an intact uteruscombined continuous5.6 yearsfemalesn = 16,608
Long-term hormone therapy for perimenopausal and postmenopausal women · The Cochrane database of systematic reviews · 4 Sep 2026

Latest

2

Journal of Clinical DensitometryHuman trial15 Sep

Cortical and trabecular bone changes associated with tibolone in postmenopausal women: A randomized, open-label study compared with estrogen therapy and placebo

Bones and joints

The Cochrane Database of Systematic ReviewsReview4 Sep

Long-term hormone therapy for perimenopausal and postmenopausal women

ENDO 2025 AbstractResearch23 Oct

SAT-783 83y Old Woman On Long-Term Hormone Replacement Therapy (HRT) for Osteoporosis (OP) Management: n of 1, Revisiting the Role of HRT in OP Management